Boston Scientific delivered another robust quarter in the second quarter of 2026, driven by sustained demand across its cardiovascular portfolio, continued commercial momentum for recently launched technologies, and broad-based global growth. The medical technology company reported net sales of $5.44 billion, represen…
Eli Lilly and Company reported a strong start to 2026, delivering exceptional first-quarter financial performance driven by sustained global demand for its cardiometabolic portfolio. The company posted revenue of $19.8 billion in Q1 2026, representing a 56% year-over-year increase, supported primarily by significant v…
The global biopharma and healthcare sector closed 2025 with a mix of resilience, portfolio transitions, and innovation-led growth. While some companies navigated patent cliffs and market normalization, others accelerated on the back of specialty medicines, biologics manufacturing, medical technologies, and vaccine pla…
Novo Nordisk A/S reported its fourth quarter and full-year 2025 financial results showing solid sales growth driven by GLP-1 diabetes and obesity care products, robust profitability, generous shareholder returns, and strategic pipeline progress. However, the company’s 2026 guidance reflects meaningful headwinds from p…
Medpace Holdings, Inc., a global clinical research organization (CRO) supporting biopharmaceutical and medical technology companies in clinical development, reported robust 2025 full-year and fourth quarter financial results with significant revenue expansion. While top-line growth and profitability measures were stro…
Gilead Sciences, Inc. reported its fourth quarter and full year 2025 financial results with modest revenue growth, solid product performance in key therapeutic franchises and improved earnings metrics, while providing guidance for 2026 against a backdrop of competitive pressures and shifting product mix. CEO Daniel O’…
AstraZeneca PLC delivered a solid full-year performance in 2025, underpinned by broad-based commercial growth, strong oncology franchise momentum, robust pipeline progression and prudent financial management. Total revenues expanded in double-digit territory on a product basis, earnings improved, and the company reite…
Bristol Myers Squibb Company a leading global biopharmaceutical company, reported fourth quarter and full-year 2025 financial results, marked by resilient performance in its growth portfolio and strategic progress across its pipeline. CEO Christopher Boerner, Ph.D., highlighted diversified revenue streams, strong fun…
Illumina, Inc., a global leader in genomic sequencing and multi-omics technologies, reported financial results for the fourth quarter and full fiscal year 2025, highlighting a return to quarterly revenue growth, solid profitability improvements, and an upbeat outlook for fiscal 2026 under CEO Jacob Thaysen. Fourth Qu…
SK Bioscience Co., Ltd. announced preliminary consolidated FY2025 financial results and fourth-quarter performance, delivering strong revenue growth driven by its expanded vaccine portfolio and the turnaround of recently acquired IDT Biologika, even as the company continues to invest heavily in R&D and capacity ex…
Page 1 of 3